ETON - Eton Pharmaceuticals, Inc. Summary, Stock Quote and News | Benzinga

Market Overview

6.280 -0.2 (-3.09%)

Data as of Dec 16, 2019

Prev. Close 6.48
Price Open 6.49
Volume 44,666
Day's Range 6.24 - 6.6
52 Wk Range 5.13 - 10.2
50 Day Moving Avg. 6.05
PE Ratio 0
Shares Outstanding 17.81M
Market Cap 111.83M

Trade ETON stock with recommended broker Ally Invest. Commissions as low as $3.95.

Analyst Rating View All Ratings

Eton Pharma 8-K Shows Submission Of Abbreviated New Drug Application For DS-300 Hospital Injectable Product Candidate; Co. Was Notified Partner Submitted Amendment To EM-100 Production Application To Address Issues Raised By FDA Benzinga NewsdeskThu, 12 Dec 2019 07:47:26 -0500
Eton Pharmaceuticals Announces Commercial Availability of Biorphen Injection Benzinga NewsdeskMon, 02 Dec 2019 07:37:14 -0500
The Week Ahead In Biotech: Aquestive Awaits FDA Decision, Arrowhead Earnings And More Shanthi RexalineSun, 24 Nov 2019 16:19:59 -0500
Eton Pharmaceuticals Q3 EPS $(0.28) Misses $(0.25) Estimate Benzinga NewsdeskThu, 14 Nov 2019 16:08:12 -0500
The Daily Biotech Pulse: Amarin Braces For Vascepa Adcom Verdict, Biotechs On A Fundraising Spree, Zosano Makes Progress With Migraine Drug Filing Shanthi RexalineThu, 14 Nov 2019 08:07:04 -0500
Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Wednesday, October 23, 2019 Benzinga NewsdeskWed, 23 Oct 2019 08:53:04 -0500
10 Biggest Price Target Changes For Wednesday Lisa LevinWed, 23 Oct 2019 08:13:07 -0500
33 Healthcare Stocks Moving In Wednesday's Pre-Market Session Lisa LevinWed, 23 Oct 2019 07:48:50 -0500
H.C. Wainwright Reiterates Buy on Eton Pharmaceuticals, Raises Price Target to $21 Vick MeyerWed, 23 Oct 2019 06:16:20 -0500
41 Biggest Movers From Yesterday Lisa LevinWed, 23 Oct 2019 04:09:46 -0500
{{ story.title }} {{ story.author }}{{ story.created }}

Show more Loading articles...

Eton Pharmaceuticals Announces Commercial Availability of Biorphen® (phenylephrine HCI) Injection Globe NewswireDec 02, 2019
Eton Pharmaceuticals Announces Third Quarter Financial Results and Highlights Business Progress Globe NewswireNov 14, 2019
Eton Pharmaceuticals Announces $10 Million Debt Facility with SWK Holdings Globe NewswireNov 13, 2019
Eton Pharmaceuticals to Report Third Quarter 2019 Financial Results on Thursday, November 14, 2019 Globe NewswireNov 06, 2019
Eton Pharmaceuticals Announces U.S. FDA Approval of Biorphen® (phenylephrine HCI) Injection Globe NewswireOct 22, 2019
Eton Pharmaceuticals to Participate in Lake Street 3rd Annual Best Ideas Growth Conference Globe NewswireSep 03, 2019
Eton Pharmaceuticals Announces Positive Results from Clinical Study Report of ET-104 Business WireAug 19, 2019
Eton Announces Second Quarter Financial Results and Highlights Business Progress Globe NewswireAug 06, 2019
Harrow Health Forms Stowe Pharmaceuticals Subsidiary to Develop Broad Spectrum Anti-Microbial Ophthalmic and Otic Therapeutics Globe NewswireAug 02, 2019
Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-105 Globe NewswireAug 01, 2019
{{ story.title }} {{ story.author }}{{ story.created }}

Show more Loading articles...

Eton Pharma files for $100M mixed shelf Seeking AlphaDec 02, 2019
Eton Pharmaceuticals Announces Commercial Availability of Biorphen® (phenylephrine HCI) Injection GuruFocusDec 02, 2019
Eton Pharmaceuticals, Inc. (ETON) CEO Sean Brynjelsen on Q3 2019 Results - Earnings Call Transcript Seeking AlphaNov 14, 2019
Eton Pharmaceuticals EPS misses by $0.03 Seeking AlphaNov 14, 2019
Eton Pharmaceuticals (ETON) Investor Presentation - Slideshow Seeking AlphaOct 22, 2019
BMY, BIIB among premarket gainers Seeking AlphaOct 22, 2019
Eton Pharmaceuticals Announces U.S. FDA Approval of Biorphen® (phenylephrine HCI) Injection GuruFocusOct 22, 2019
Eton Pharma up 20% premarket on FDA nod for Biorphen Seeking AlphaOct 22, 2019
MKM bearish on Curaleaf and Aurora Cannabis in premarket analyst action Seeking AlphaSep 20, 2019
Eton Pharmaceuticals to Participate in Lake Street 'rd Annual Best Ideas Growth Conference GuruFocusSep 03, 2019
{{ story.title }} {{ story.author }}{{ story.created }}

Show more Loading articles...

Earnings View Earnings

Q3 2019	EST	Actual	Surprise
EPS:	-0.250	-0.280	-0.0300
Rev:		0.00

Q4 2019	EST	Actual	Surprise
EPS:	Expected 2020-03-23
Rev:	Expected 2020-03-23

Company Profile

Read More

Visit company website

Brokerage Center

Compare All Online Brokerages

Book A Demo

Learn How You Can Succeed In The Market With Benzinga Pro

Fastest Market News

Real-Time News Alerts

Customizable News Filters

Book A Demo